Multiple Myeloma · line 1 · Lenalidomide + Dexamethasone continuous (Rd, MAIA control arm — MM 1L transplant-ineligible)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-RD-CONTINUOUS |
| ID | IND-MM-1L-RD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-09 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-MAIA-FACON-2019 SRC-NCCN-MM-2025 |
Notes
STUB — requires clinical co-lead signoff before publication. Standard counterpart to IND-MM-1L-DARA-RD for two-plan output in transplant- ineligible NDMM (CHARTER §2). Rd continuous is the standard-access option when daratumumab funding is unavailable (common in Ukraine where НСЗУ does not currently reimburse daratumumab). MAIA trial context (Facon NEJM 2019, PMID 30926586): this indication represents the control arm — Rd alone. D-Rd improved PFS HR 0.56 and 5-yr OS HR 0.66 vs Rd. In a well-resourced setting, D-Rd is preferred; Rd is the fallback when daratumumab is inaccessible. FIRST trial (Benboubker NEJM 2014, PMID 25184863): Rd continuous vs Rd18 (18 cycles fixed) vs MPT — Rd continuous showed superior PFS (26 months) vs MPT (21.9 months). Established the "until progression" strategy. Scope gate: fit_for_transplant: false restricts IND-MM-1L-RD to transplant-ineligible patients. For transplant-eligible standard-plan patients, see IND-MM-1L-VRD (VRd backbone + ASCT pathway).
Used By
Algorithms
ALGO-MM-1L- ALGO-MM-1L
Indication
IND-MM-1L-DARA-RD- IND-MM-1L-DARA-RD